Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.

Yunes DolehLincy S LalCori Blauer-PetersenGiovanni AnticoMichael Pishvaian

Published in: Cancer medicine (2020)

A large proportion (57%) of patients with unresectable/metastatic pancreatic cancer did not receive chemotherapy. Healthcare costs were higher for fluorouracil-based regimens, while lower for gemcitabine-based regimens. Survival rates were within expectations for advanced pancreatic cancer.

Keyphrases

locally advanced
healthcare
squamous cell carcinoma
small cell lung cancer
health insurance
radiation therapy
metabolic syndrome
skeletal muscle
weight loss